Notes to the Financial Statements Note 1: Segment Information continued The table below reconciles statutory results for key line items to the segment report. Statutory results Amortisation of acquired IP Restructuring and impairment expenses Net gain on business disposals Segment results Year ended 30 June (US$m) 2026 2025 2026 2025 2026 2025 2026 2025 2026 2025 Gross profit 8,075 8,079 379 364 — — — — 8,454 8,443 Selling and marketing expenses (1,691) (1,616) — — — — — — (1,691) (1,616) Research and development expenses (1,223) (1,359) — — — — — — (1,223) (1,359) General and administrative expenses (920) (1,000) — — — — — — (920) (1,000) Restructuring and impairment expenses (7,923) — — — 7,923 — — — — — Net gain on business disposals — 30 — — — — — (30) — — EBIT / Underlying EBIT (3,682) 4,134 379 364 7,923 — — (30) 4,620 4,468 (Loss)/profit before tax / Underlying profit before tax (4,087) 3,724 379 364 7,923 — — (30) 4,215 4,058 Income tax benefit/(expense) 1,101 (588) (57) (57) (1,923) — — — (879) (645) NPAT (loss) / Underlying NPATA (2,986) 3,136 322 307 6,000 — — (30) 3,336 3,413 - NPAT (loss) / Underlying NPATA attributable to CSL Limited shareholders (2,579) 3,002 261 247 5,416 — — (30) 3,098 3,219 - NPAT (loss) / Underlying NPATA attributable to non-controlling interests (407) 134 61 60 584 — — — 238 194 Basic (loss)/earnings per share / Underlying NPATA per share (US$) (5.35) 6.20 0.54 0.51 11.24 — — (0.06) 6.43 6.65 Other segment information CSL Behring CSL Vifor CSL Seqirus Consolidated Entity US$m US$m US$m US$m Segment assets and liabilities 2026 2025 2026 2025 2026 2025 2026 2025 Segment assets 24,972 24,495 4,333 10,235 4,341 4,674 33,646 39,404 Segment liabilities 14,686 14,948 1,208 1,674 1,445 1,375 17,339 17,997 Segment assets and liabilities disclosed above exclude intercompany receivables, payables and investments in subsidiaries which have been eliminated. Certain segment assets have been impaired during the year ended 30 June 2026, refer to Note 3 for further details. Segment cash flow information Cash payments for property, plant and equipment (PPE) 602 505 26 12 18 119 646 636 Cash payments for intangibles 256 114 117 98 258 150 631 362 Cash payments for property, plant and equipment during the year ended 30 June 2026 include investment made into the Horizon 2 immunoglobulin yield improvement program and advancing the Group's global asset management program including the expansion of manufacturing footprint in the U.S. Cash payments for intangible assets during the year ended 30 June 2026 include investment in product intellectual property, including an upfront payment to VarmX BV in support of the development of VMX-C001, a novel treatment for the reversal of Factor Xa direct oral anticoagulants. Cash payments for intangible assets also include capitalised development expenditures associated with regulatory commitments relating to certain commercialised products, including vaccines. 96 96 Financial Report
RkJQdWJsaXNoZXIy MjE2NDg3